As EPP suppressed the STAT3 and MET/AKT pathways, which stimulate tumor growth and confer EGFR TKI resistance, EPP could be applied not only to EGFR TKI-naïve or -sensitive NSCLC, but also to EGFR TKI-resistant NSCLC. This evidence concerns the gene AKT1 and neoplasm.